NCCN Guidelines for Patients® | Colon Cancer - page 31

NCCN Guidelines for Patients
Colon Cancer, Version 1.2014
to surface receptors within cancer cells and stop
growth signals.
Regorafenib is made as a pill that is taken once a day.
However, it is taken in cycles consisting of treatment
days followed by a period of no treatment. The cycle
for regorafenib consists of 3 weeks of treatment then
1 week of no treatment. The cycle is then repeated.
Common side effects of regorafenib include feeling
tired or week, fever, and diarrhea. Your hands and
feet may become red and have pain. This is called
hand-foot syndrome. Rare but serious side effects
include severe liver damage, heart attack, and
Like bevacizumab, ziv-aflibercept also targets
VEGF. It works by acting as a decoy. VEGF thinks
bevacizumab is a surface receptor and attaches to
it. Thus, ziv-aflibercept traps VEGF so it is unable
to bind to the real receptor—hence its other name,
VEGF-trap. By trapping VEGF, cancer cells will not
receive the blood they need to live.
Ziv-aflibercept is always given with chemotherapy. It
is given by infusion in about 1 hour every two weeks.
Common side effects include diarrhea, mouth sores,
high blood pressure, feeling tired, voice changes, and
nose bleeds. You may also experience blood clots,
urinary tract infection, and darkening of the skin. Rare
but serious side effects include stroke, holes in the
intestine, bleeding in the brain or lungs, and kidney
Overview of cancer treatments Targeted therapy
1...,21,22,23,24,25,26,27,28,29,30 32,33,34,35,36,37,38,39,40,41,...88
Powered by FlippingBook